title: Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study.
abstract: BACKGROUND
  Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these patients are scarce.
  
  
  METHODS
  A prospective multicenter study was conducted to assess the immunogenicity of HBV vaccination in 54 patients with an isolated anti-HBc profile and undetectable HIV load. They were vaccinated with 1 dose (20 µg) of recombinant HBV vaccine. Those with an anti-HBV surface antibody (anti-HBs) level of <10 mIU/mL 4 weeks after vaccination received 3 additional double doses (40 µg) at weeks 5, 9, and 24.
  
  
  RESULTS
  At week 4, 25 patients (46%) were responders. Only the ratio of CD4(+) T cells to CD8(+) T cells was associated with this response in multivariate analysis (odds ratio for +0.1, 1.32; 95% confidence interval, 1.07-1.63; P = .008). At week 28 and month 18, 58% of these patients (14 of 24) and 50% (10 of 20), respectively, maintained anti-HBs level of ≥10 mIU/mL.Among nonresponding patients at week 4, who received further vaccinations, 89% (24 of 27) and 81% (21 of 26) had an anti-HBs level of ≥10 mIU/mL at week 28 and month 18, respectively. The preS2-specific interferon γ T-cell response increased between week 0 and week 28 in patients who finally responded to reinforced vaccination (P = .03).
  
  
  CONCLUSIONS
  All of the patients with an isolated anti-HBc profile who did not have an anti-HBs titer of >100 mIU/mL 4 weeks after a single recall dose of HBV vaccine should be further vaccinated with a reinforced triple double-dose scheme.
authors.affiliation: Département d'infectiologie, CHU de Dijon, MERS UMR1347, Université de Bourgogne, Dijon Cedex.
authors.forename: Lionel
authors.initials: L
authors.lastname: Piroth
authors.affiliation: Université Paris Descartes, Sorbonne Paris Cité; INSERM, CIC 1417 , F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin Pasteur.
authors.forename: Odile
authors.initials: O
authors.lastname: Launay
authors.affiliation: Laboratoire de Pathogenèse des virus de l'hépatite B, Département de Virologie, Institut Pasteur, INSERM U994, Paris.
authors.forename: Marie-Louise
authors.initials: ML
authors.lastname: Michel
authors.affiliation: INSERM, CIC 1432, Centre d'investigation clinique (Epidémiologie clinique/ essais cliniques), CHU de Dijon.
authors.forename: Abderrahmane
authors.initials: A
authors.lastname: Bourredjem
authors.affiliation: Département des Maladies Infectieuses, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, INSERM U1052.
authors.forename: Patrick
authors.initials: P
authors.lastname: Miailhes
authors.affiliation: Service des Maladies Infectieuses, CHU de Tourcoing.
authors.forename: Faiza
authors.initials: F
authors.lastname: Ajana
authors.affiliation: Service des Maladies Infectieuses, CHU de Besançon, Université de Franche-Comté
authors.forename: Catherine
authors.initials: C
authors.lastname: Chirouze
authors.affiliation: Service de Médecine Interne, Hôpital Foch,Suresnes.
authors.forename: David
authors.initials: D
authors.lastname: Zucman
authors.affiliation: Laboratoire de Virologie, Hôpitaux Universitaires, Strasbourg.
authors.forename: Marie-Josee
authors.initials: MJ
authors.lastname: Wendling
authors.affiliation: Université Paris Descartes, Sorbonne Paris Cité; INSERM, CIC 1417 , F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin Pasteur.
authors.forename: Dani
authors.initials: D
authors.lastname: Nazzal
authors.affiliation: INSERM, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Sorbonne Universités, UPMC Univ Paris 06, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Public Health Unit, Saint-Antoine Hospital, AP-HP, Paris.
authors.forename: Fabrice
authors.initials: F
authors.lastname: Carrat
authors.affiliation: Center for HIV infection care, Hôpitaux Universitaires, Strasbourg Cedex, France.
authors.forename: David
authors.initials: D
authors.lastname: Rey
authors.affiliation: INSERM, CIC 1432, Centre d'investigation clinique (Epidémiologie clinique/ essais cliniques), CHU de Dijon.
authors.forename: Christine
authors.initials: C
authors.lastname: Binquet
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D015497:HIV-1; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000276:immunology / Q000302:isolation & purification*; D006512:Hepatitis B Core Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D000071497:Immunogenicity, Vaccine; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
chemical_list: D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic
keywords: HBV; HIV; immunology; isolated anti-HBc; vaccination